CANCER RESEARCH UK and CANCER RESEARCH TECHNOLOGY LIMITED and MONOPAR THERAPEUTICS LLC CLINICAL TRIAL AND OPTION AGREEMENT (CTOA)Clinical Trial and Option Agreement • March 26th, 2018 • Monopar Therapeutics • Pharmaceutical preparations • New York
Schedule 1 Company Patent Rights Schedule 2 Report Synopsis Headings Schedule 3 Licence from CRT to Company Schedule 4 No Fault Compensation Scheme Schedule 5 Assignment and Licence from Company to CRT Schedule 6 Protocol Schedule 7 Company Materials Schedule 8 Back-Up Antibodies Schedule 9 XOMA Licence Schedule 10 Progress Reports Schedule 11 Clinical Protocol Summary Schedule 12 Escrow Agreement Schedule 13 Technical Agreement
ContractClinical Trial and Option Agreement • November 10th, 2014 • Asterias Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 24b-2 of the Exchange Act of 1934, as amended. Confidential Portions are marked: [***].
Clinical Development Partnerships Clinical Trial and Option Agreement Vaccitech Oncology Limited and Cancer Research Technology Limited and Cancer Research UKClinical Trial and Option Agreement • April 9th, 2021 • Vaccitech PLC • Pharmaceutical preparations • England and Wales
Company VACCITECH ONCOLOGY LIMITED (“VOLT”), a company registered in England and Wales under number 11655405 with registered office at The Schrodinger Building 2nd Floor, Heatley Road, Oxford Science Park, Oxford, Oxfordshire, England, OX4 4GE
ContractClinical Trial and Option Agreement • January 13th, 2015 • Asterias Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Confidential treatment has been requested for certain portions of this exhibit pursuant to a request for confidential treatment under Rule 24b-2 of the Exchange Act of 1934, as amended. Confidential materials omitted and filed separately with the Securities and Exchange Commission. Confidential portions are marked: [***].
Chandler Robinson Chief Executive Officer Monopar Therapeutics LLC 598 Rockefeller Road Lake Forest, IL USA 60045 Cancer Research UK Angel Building 407 St John Street London EClV 4AD United KingdomClinical Trial and Option Agreement • March 26th, 2018 • Monopar Therapeutics • Pharmaceutical preparations
SECOND AMENDMENT TO CLINICAL TRIAL AND OPTION AGREEMENTClinical Trial and Option Agreement • August 6th, 2020 • Lineage Cell Therapeutics, Inc. • Biological products, (no disgnostic substances)
CANCER RESEARCH UK a company limited by guarantee registered under number 4325234 and a charity registered under number 1089464 of 2 Redman Place, Stratford, London, E20 1JQ, England (the “Charity”);
